| Category | Shares Offered | Lots | Amount (₹) |
|---|---|---|---|
| QIB (Qualified) | 21,000 (0.89%) | — | — |
| NII (HNI) | 10,89,000 (46.34%) | 3 | ₹₹3,72,000 |
| Retail | 10,90,000 (46.38%) | 2 | ₹₹2,48,000 |
| Market Maker | 1,50,000 (6.38%) | — | — |
Amount in ₹ Crore
| Metric | 31 Oct 2025 | 31 Mar 2025 | 31 Mar 2024 |
|---|---|---|---|
| Revenue | 36.93 | 58.54 | 27.66 |
| PAT | 6.06 | 8.61 | 2.93 |
| EBITDA | 6.51 | 9.09 | 5.26 |
| Net Worth | 36.47 | 30.42 | 15.06 |
| Total Assets | 45.57 | 39.98 | 22.68 |
| Reserves | 30.04 | 23.98 | 9.95 |
| Borrowings | 4.81 | 5.05 | 2.86 |
Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals — including high-cost oral and injectable medications used to treat complex chronic conditions — across both domestic and international markets.
The company’s portfolio includes a wide range of speciality pharmaceutical finished formulations such as capsules, creams, eye drops, gels, infusions, inhalations and inhalers, injections, nasal sprays, ointments, ophthalmic solutions, oral solutions, oral suspensions, sachets, suspensions, and tablets.
Through wide-ranging distribution channels, the company has built a trusted reputation with clients across more than 20 states in India and over 35 countries worldwide.
Speciality Medicines Limited offers over 650 products (as of July 31, 2024) under the unregistered category, with a particular focus on therapeutic areas like:
Additionally, the company’s product range includes human and animal medicines, vaccines, and plasma products — all sourced from manufacturers that comply with global quality standards like EUGMP and PICS.
Global Expansion and Registrations
As of July 31, 2024, Speciality Medicines Limited has:
As of July 31, 2024, Speciality Medicines Limited employs a team of 20 permanent employees across various departments, contributing to the company’s smooth and efficient operations.